Inactive Instrument
Five Prime Therapeutics, Inc. Share Price
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 60,000 | 0.1288% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +0.24% | -1.54% | +52.85% | +71.85% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.32% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +417.78% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -15.41% | 23.13B | |
| -5.95% | -2.58% | +29.53% | -9.47% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -30.65% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +314.96% | 15.2B | |
| -6.91% | -5.83% | +25.17% | +644.30% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +189.74% | 14.06B | |
| Average | -2.49% | -2.62% | +40.54% | +184.05% | 25.95B | |
| Weighted average by Cap. | -2.78% | -2.36% | +39.55% | +143.13% |
Employees
51
Choose MarketScreener 
